Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 376 participants.

Also called NCT04824911

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 376 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04824911
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04824911. Non-randomized; no masking; primary purpose treatment. Start 2021-03-23 (actual); primary completion 2025-02-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease
Acronym
SATBRAD
Condition
Acute Stroke
Condition
Dual Antiplatelet Therapy
Condition
Statin
Intervention (Drug)
Clopidogrel
Intervention (Drug)
Aspirin
Intervention (Drug)
Atorvastatin
Intervention (Drug)
Rosuvastatin
Lead sponsor
Chang Gung Memorial Hospital (class: other)

Record details

Record id
cardio:ct-nct04824911
Content hash
ac9d0a066f20870338a3844c50156ebb3414ada8352d136de5540ed2beea8284